Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion
Authors:
Open Access
- 26 October 2012
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 107 (6) , 1-14
Abstract
Increased levels of extracellular superoxide dismutase (ecSOD) induced by preconditioning or gene therapy protect the heart from ischemia/reperfusion injury. To elucidate the mechanism responsible for this action, we studied the effects of increased superoxide scavenging on nitric oxide (NO) bioavailability in a cardiac myocyte-specific ecSOD transgenic (Tg) mouse. Results indicated that ecSOD overexpression increased cardiac myocyte-specific ecSOD activity 27.5-fold. Transgenic ecSOD was localized to the sarcolemma and, notably, the cytoplasm of cardiac myocytes. Ischemia/reperfusion injury was attenuated in ecSOD Tg hearts, in which infarct size was decreased and LV functional recovery was improved. Using the ROS spin trap, DMPO, electron paramagnetic resonance (EPR) spectroscopy demonstrated a significant decrease in ROS in Tg hearts during the first 20 min of reperfusion. This decrease in ROS was accompanied by an increase in NO production determined by EPR using the NO spin trap, Fe-MGD. Attenuated ROS in ecSOD Tg myocytes was also supported by decreased production of peroxynitrite (ONOO−). Increased NO bioavailability was confirmed by attenuated guanylate cyclase-dependent (p-VASP) signaling. In conclusion, attenuation of ROS levels by cardiac-specific ecSOD overexpression increases NO bioavailability in response to ischemia/reperfusion and protects against reperfusion injury. These findings are the first to demonstrate increased NO bioavailability with attenuation of ROS by direct measurement of these reactive species (EPR, reactive fluorescent dyes) with cardiac-specific ecSOD expression. This is also the first indication that the predominantly extracellular SOD isoform is capable of cytosolic localization that affects myocardial intracellular signal transduction and function.Keywords
This publication has 69 references indexed in Scilit:
- Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injuryBasic Research in Cardiology, 2012
- Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequencesBasic Research in Cardiology, 2011
- Chronic AMD3100 antagonism of SDF-1α–CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarctionJournal of Molecular and Cellular Cardiology, 2010
- Translating novel strategies for cardioprotection: the Hatter Workshop RecommendationsBasic Research in Cardiology, 2010
- Extracellular superoxide dismutase regulates cardiac function and fibrosisJournal of Molecular and Cellular Cardiology, 2009
- Endogenous S -nitrosothiols protect against myocardial injuryProceedings of the National Academy of Sciences, 2009
- Cardiac Myocyte–Specific Expression of Inducible Nitric Oxide Synthase Protects Against Ischemia/Reperfusion Injury by Preventing Mitochondrial Permeability TransitionCirculation, 2008
- Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarctionFree Radical Biology and Medicine, 2008
- Stromal Cell–Derived Factor-1α Confers Protection Against Myocardial Ischemia/Reperfusion InjuryCirculation, 2007
- Protein kinase activation and myocardial ischemia/reperfusion injuryCardiovascular Research, 2004